ArrowMark Colorado Holdings LLC Invests $3.39 Million in Septerna, Inc. (NASDAQ:SEPN)

ArrowMark Colorado Holdings LLC bought a new stake in Septerna, Inc. (NASDAQ:SEPN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 147,886 shares of the company's stock, valued at approximately $3,387,000. ArrowMark Colorado Holdings LLC owned approximately 0.33% of Septerna at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Tower Research Capital LLC TRC bought a new stake in shares of Septerna in the fourth quarter worth $25,000. New York State Common Retirement Fund acquired a new stake in shares of Septerna during the fourth quarter worth $32,000. Legal & General Group Plc acquired a new position in Septerna in the fourth quarter valued at $42,000. Summit Investment Advisors Inc. bought a new stake in shares of Septerna during the 4th quarter valued at about $45,000. Finally, PNC Financial Services Group Inc. bought a new position in Septerna during the fourth quarter worth $61,000.

Insider Activity at Septerna

In other Septerna news, CFO Gil M. Labrucherie bought 10,500 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The stock was purchased at an average cost of $5.51 per share, with a total value of $57,855.00. Following the completion of the acquisition, the chief financial officer now owns 10,500 shares in the company, valued at $57,855. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alan Ezekowitz bought 41,355 shares of Septerna stock in a transaction dated Thursday, March 6th. The stock was acquired at an average price of $6.00 per share, for a total transaction of $248,130.00. Following the completion of the acquisition, the director now owns 104,101 shares in the company, valued at approximately $624,606. The trade was a 65.91 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 74,346 shares of company stock valued at $439,670 over the last ninety days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on SEPN shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $50.00 price objective on shares of Septerna in a research note on Tuesday, February 11th. Wells Fargo & Company dropped their price objective on Septerna from $14.00 to $11.00 and set an "equal weight" rating on the stock in a research note on Friday, March 28th.

Septerna Price Performance

Shares of SEPN stock traded down $0.26 during trading hours on Friday, reaching $6.69. The company's stock had a trading volume of 69,392 shares, compared to its average volume of 410,943. The firm's fifty day simple moving average is $6.17 and its 200 day simple moving average is $14.60. Septerna, Inc. has a one year low of $4.17 and a one year high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The business had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.13 million. On average, equities research analysts anticipate that Septerna, Inc. will post -7.11 earnings per share for the current year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.